Key result
RAAS inhibition via ACE inhibitors or ARBs improves insulin sensitivity for cardiovascular prevention.
Why the study?
Insulin resistance and hyperinsulinaemia play a key role in cardiovascular disease, prompting interest in pharmacological strategies that interfere with insulin resistance in cardiovascular prevention.
Do RAAS inhibitors (ACE inhibitors and ARBs) improve insulin resistance and prevent cardio-metabolic diseases in patients at risk?
Design
Review
Authors
Loading...
May favor RAAS inhibitors in metabolic CV risk; leaves open confirmatory RCTs.
Do RAAS inhibitors (ACE inhibitors and ARBs) improve insulin resistance and prevent cardio-metabolic diseases in patients at risk?
RAAS inhibitors (ACE inhibitors and ARBs) improve insulin sensitivity and reduce the risk of new-onset type 2 diabetes, making them a preferred choice for cardiovascular prevention in patients with metabolic abnormalities.
Valente et al. (2021) conducted a review in Insulin resistance and cardiovascular disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors was evaluated. Pharmacological inhibition of the renin-angiotensin-aldosterone system with ACE inhibitors or ARBs improves insulin sensitivity and represents a key strategy in cardiovascular prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: